Floatz logo

Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer

Triple-Negative Breast Carcinoma

Explore 428 assets in Triple-Negative Breast Carcinoma →
Floatz Rating
CCC51/100
Confidence
Indicative
v0.2
Sponsor
Stephen Shiao
Modality
monoclonal_antibody
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
TrialPhaseStatusNPrimary endpointReadout
NCT07015853CT.gov
ASTRAEA: ReinvigorAting ReSponse To ImmunotheRApy in MEtAstatic TNBC With Combination Myeloid Inhibition and Radiation
—Not Yet Recruiting———
NCT05491226CT.gov
Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
—Recruiting———

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Triple-Negative Breast Carcinoma

AssetSponsorPhaseRating
Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer (this asset)Stephen ShiaoP2CCC · 51
CarboplatinM.D. Anderson Cancer CenterP4BB
CapivasertibAstraZenecaP3BB
CyclophosphamideM.D. Anderson Cancer CenterP4BB
VeliparibNational Cancer Institute (NCI)P3BB
EnzalutamideNuvation Bio Inc.P2BB
AtezolizumabEuropean Institute of OncologyP3BB
FamitinibFudan UniversityP3BB
EpirubicinM.D. Anderson Cancer CenterP4BB

+42 more in the Triple-Negative Breast Carcinoma cohort

Other indications for Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer

IndicationSponsorPhaseRating
Idiopathic Pulmonary Fibrosis—P2CCC · 51
Breast Cancer—P2CCC · 50
Hodgkins Lymphoma—P2CCC · 48

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Immunoglobulin G4, Anti-(Human Colony-Stimulating Factor 1 Receptor) (Human-Rattus Norvegicus Monoclonal Sndx-6352 .Gamma.4-Chain), Disulfide With Human-Rattus Norvegicus Monoclonal Sndx-6352 .Kappa.-Chain, Dimer in Triple-Negative Breast Carcinoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/immunoglobulin-g4-anti-human-colony-stimulating-factor-1-receptor-human-rattus-norvegicus-monoclonal-sndx-6352-gamma4-chain-disulfide-with-human-rattus-norvegicus-monoclonal-sndx-6352-kappa-chain-dimer-triple-negative-breast-carcinoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →